Following the Biosimilar Breadcrumbs: When Health Systems and Manufacturers Approach Forks in the Road.
Over 2 years have passed since the first biosimilar was approved for use in the United States. Despite a relatively slow start, biosimilar activity has significantly increased in recent months. Biologics are the most expensive drug category in the United States, costing patients hundreds or even thousands of dollars per year. Biosimilars have the potential to significantly decrease cost of care, increase access, and improve patient outcomes. In order to realize the potential savings, biosimilar manufacturers, health care providers, and payers must develop strategies to navigate the challenging health care environment and understand where and how biosimilars bring the most value to patients. Trends in biosimilar uptake within health systems have demonstrated the need for manufacturers to deploy a robust product strategy before and after launch. In order to gain high-level insight from health system experiences with the first infliximab biosimilar approved in the United States, a questionnaire was distributed to pharmacy representatives from health systems during March and April 2017. Responses from more than 50 health systems across the country revealed that the key barriers and challenges faced with biosimilar uptake include payers and reimbursement, interchangeability, provider preference, and cost. This article explores health system experiences with biosimilars thus far and describes real-world implementation strategies. In addition, insights into manufacturer considerations are highlighted with regard to financial, clinical, and operational decisions. The author received no outside funding support and has nothing to disclose.